Beyond Amyloid: Rethinking the Foundations of Alzheimer's Disease Pathogenesis and Therapy

Area of Science:

• Neuroscience
• Neuropathology
• Biomedical Research

Background:

• The amyloid cascade hypothesis has dominated Alzheimer's disease (AD) research for over 30 years, positing amyloid-beta (Aβ) accumulation as the primary cause of neurodegeneration.
• Despite extensive research and drug development targeting Aβ, clinical trials have yielded limited success, indicating potential limitations of the amyloid-centric model.

Purpose of the Study:

• To re-evaluate the amyloid cascade hypothesis in light of recent clinical trial data, biomarker studies, and neuropathological findings.
• To propose an integrative, multi-faceted view of AD pathogenesis that moves beyond a singular focus on amyloid-beta.

Main Methods:

• Review of contemporary Alzheimer's disease clinical trial results and their correlation with amyloid-lowering strategies.
• Analysis of biomarker trajectories and neuropathological observations in AD patients.
• Examination of scientific, regulatory, and structural factors influencing AD research and drug development.

Main Results:

• Amyloid plaques may represent intermediate products rather than the primary drivers of AD pathogenesis.
• Amyloid-lowering treatments have not consistently translated into clinically meaningful cognitive benefits, highlighting a disconnect between target engagement and patient outcomes.
• Recent findings suggest AD is a complex, staged process involving tau pathology, neuroinflammation, vascular factors, and aging.

Conclusions:

• The long-standing amyloid cascade hypothesis requires re-evaluation due to its translational shortcomings.
• An integrative model incorporating tau, neuroimmunity, vascular health, and aging is crucial for advancing AD understanding and treatment.
• Future progress in AD depends on earlier, stage-matched interventions, combination therapies, and patient-centered regulatory standards.